Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of IM83 CAR-T in Advanced Liver Tumors
NCT05123209Phase 1Unknown
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Aug 2021
- Primary completion
- Aug 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of IM83 in hepatocellular carcinoma (HCC) (2 arms), sponsored by Immunochina Pharmaceuticals. Primary endpoint: Incidence of adverse events at 28 days. Status: unknown.
02
Drugs
IM83
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05123209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05123209.